Apellis Pharmaceuticals, Inc.
APLSHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Apellis Pharmaceuticals, Inc. focuses on Biotechnology services and products. Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high. With a market capitalization of $5.25B, it sits in mid-cap territory. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).
Market Cap
$5.25B
Beta
-0.25
P/E (TTM)
38.35
P/E (Fwd)
-120.68
EPS (TTM)
$1.07
EPS (Fwd)
$-0.34
ROE
46.0%
ROA
10.9%
Cash
$406.2M
Total Debt
$475.8M
Free CF
-$63.7M
52W Change
135.1%
Annual Financials
Cash vs Debt
On the balance sheet, APLS has $406.2M in cash with $475.8M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow is running at -$63.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at 46.0%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 10.9% further supports the picture of efficient asset utilization. Revenue has grown from $75.4M (2022) to $1.00B (2025), reflecting a 1231% increase over the period.
The relatively low beta of -0.25 suggests APLS is a less volatile holding compared to the broader index. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Apellis Pharmaceuticals, Inc. and its sector.